🌍·2h agoIndustry
All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study
Publisher
E
Eledon Pharmaceuticals
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Eledon Pharmaceuticals
- Region
- 最新
- Scope
- Industry
- Published
- July 16, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on eledon.com
Leave the platform to read the original full article on the publisher site.
Source: Eledon Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
Eledon Pharmaceuticals/2h ago
Tegoprubart Sustains Increased eGFR Longterm Compared to Tacrolimus
Allogene Therapeutics/6h ago
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics/6h ago
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Techcyte/2h ago